These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8896671)

  • 1. Clinical relevance of 24 h blood pressure control by 1,4-dihydropyridines.
    Leenen FH
    Am J Hypertens; 1996 Oct; 9(10 Pt 2):97S-104S; discussion 108S-109S. PubMed ID: 8896671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,4-Dihydropyridines versus beta-blockers for hypertension: are either safe for the heart?
    Leenen FH
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):397-402. PubMed ID: 8924051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of cardiac hypertrophy by 1,4 dihydropyridines in hypertensive patients.
    Leenen FH
    J Hypertens Suppl; 1998 Oct; 16(5):S9-15. PubMed ID: 9868999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there any difference between intermediate-acting and long-acting calcium antagonists in diurnal blood pressure and autonomic nervous activity in hypertensive coronary artery disease patients?
    Hoshide S; Kario K; Mitsuhashi T; Ikeda U; Shimada K
    Hypertens Res; 2000 Jan; 23(1):7-14. PubMed ID: 10737129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines.
    Ruzicka M; Leenen FH
    Am J Hypertens; 1996 Jan; 9(1):86-94. PubMed ID: 8834712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril.
    Leenen FH; Myers MG; Joyner CD; Toal CB
    Can J Cardiol; 2002 Dec; 18(12):1285-93. PubMed ID: 12518180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study.
    Lefebvre J; Poirier L; Archambault F; Jewell D; Reed CV; Lacourcière Y
    Can J Cardiol; 1998 May; 14(5):682-8. PubMed ID: 9627524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent blood pressure control: potential consequences for outcome.
    Leenen FH
    Can J Cardiol; 1999 May; 15 Suppl C():13C-18C. PubMed ID: 10380687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive effects of long-acting calcium channel blockers on hemodialysis days--a randomized crossover trial between benidipine and nifedipine CR.
    Kojima M; Taniguchi M; Sato K; Ueda R; Dohi Y
    Nephron Clin Pract; 2004; 97(2):c49-53. PubMed ID: 15218330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics.
    Wenzel RR; Allegranza G; Binggeli C; Shaw S; Weidmann P; Lüscher TF; Noll G
    J Am Coll Cardiol; 1997 Jun; 29(7):1607-14. PubMed ID: 9180126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. Italian Nifedipine GITS Study Group.
    Zanchetti A
    J Hypertens Suppl; 1994 Nov; 12(8):S97-106. PubMed ID: 7707165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lercanidipine in hypertension.
    Borghi C
    Vasc Health Risk Manag; 2005; 1(3):173-82. PubMed ID: 17319103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.
    Antza C; Stabouli S; Kotsis V
    Vasc Health Risk Manag; 2016; 12():443-451. PubMed ID: 27895487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.
    Grundy JS; Foster RT
    Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lercanidipine : a review of its efficacy in the management of hypertension.
    Bang LM; Chapman TM; Goa KL
    Drugs; 2003; 63(22):2449-72. PubMed ID: 14609358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
    Barrios V; Escobar C; de la Figuera M; Llisterri JL; Honorato J; Segura J; Calderón A
    Cardiovasc Ther; 2008; 26(1):2-9. PubMed ID: 18466416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of calcium antagonists on the cardiovascular system: experience with lacidipine.
    Kuschnir E
    Drugs; 1999; 57 Suppl 1():11-7. PubMed ID: 10529078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [24-hour perfect BP-lowering therapy using long-acting dihydropyridine calcium channel blockers].
    Eguchi K
    Nihon Rinsho; 2014 Aug; 72(8):1461-5. PubMed ID: 25167753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation.
    Fogari R; Preti P; Zoppi A; Corradi L; Pasotti C; Rinaldi A; Mugellini A
    Am J Hypertens; 2005 May; 18(5 Pt 1):577-83. PubMed ID: 15882537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.